PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
PDS Biotechnology(US:PDSB) Globenewswire·2026-04-15 20:4578% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials performed in unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases, which constitute the majority of mCRC, and in which immune checkpoint inhibitors have been unsuccessful PRINCETON, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Na ...